Trastuzumab Deruxtecan Demonstrates Sustained Efficacy in HER2+ mCRC

Trastuzumab deruxtecan demonstrated durable responses and a safety profile that was consistent with findings from the primary analysis of the phase 2 DESTINY-CRC01 trial in pretreated patients with HER2-expressing metastatic colorectal cancer, according to updated results of the study. Fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) demonstrated durable responses and a safety...